Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
The Journal of Biological Chemistry|December 29, 2012
Molecular mechanism by which a potent hepatitis C virus NS3-NS4A protease inhibitor overcomes emergence of resistanceJeff A O'Meara, Christopher T Lemke, Cédrickx Godbout, et al.
Protein Science : a Publication of the Protein Society|August 19, 2016
Point mutations at the catalytic site of PCSK9 inhibit folding, autoprocessing, and interaction with the LDL receptorColin W Garvie, Cara V Fraley, Nadine H Elowe, et al.
Bioorganic & Medicinal Chemistry Letters|April 16, 2013
Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 1: addressing configurational instability through scaffold modificationLee D Fader, Serge Landry, Sébastien Morin, et al.
ACS Chemical Biology|March 19, 2013
Novel inhibitor binding site discovery on HIV-1 capsid N-terminal domain by NMR and X-ray crystallographyNathalie Goudreau, Christopher T Lemke, Anne-Marie Faucher, et al.
Chemmedchem|February 13, 2013
Monitoring binding of HIV-1 capsid assembly inhibitors using (19)F ligand-and (15)N protein-based NMR and X-ray crystallography: early hit validation of a benzodiazepine seriesNathalie Goudreau, René Coulombe, Anne-Marie Faucher, et al.
Antimicrobial Agents and Chemotherapy|July 3, 2013
Discovery of novel small-molecule HIV-1 replication inhibitors that stabilize capsid complexesLouie Lamorte, Steve Titolo, Christopher T Lemke, et al.
Bioorganic & Medicinal Chemistry Letters|June 6, 2013
Synthesis and optimization of a novel series of HCV NS3 protease inhibitors: 4-arylproline analogsFrançois Bilodeau, Murray D Bailey, Punit K Bhardwaj, et al.
Cancer Discovery|January 18, 2024
Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C CancersDouglas A Rubinson, Noritaka Tanaka, Ferran Fece de la Cruz, et al.
Bioorganic & Medicinal Chemistry Letters|April 23, 2013
Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 2: structure-activity relationships (SAR) of the C3-phenyl moietyLee D Fader, Serge Landry, Sylvie Goulet, et al.
Bioorganic & Medicinal Chemistry Letters|November 6, 2012
Inhibition of HIV-1 capsid assembly: optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1-yl)-1H-benzimidazole scaffoldMartin Tremblay, Pierre Bonneau, Yves Bousquet, et al.
Pageof 4